Merck ($MRK) execs weren't happy when the FDA stripped its breakthrough therapy designation for their closely watched hepatitis C combo. But the agency has now relented--at least partly. The pharma giant said it's getting two new BTD titles in small subgroups of patients to replace the broader breakthrough tag that it lost. Report